PF-04217903 Size:2mg solid 22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10

22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10

Compared with the OVX + Veh group

Mavoglurant (1 nM-10 μM

and given that 305 μM Oseltamivir phosphate treatment impaired cell metabolic activity

but Not Jurkat Cells

PF-04217903 Size:2mg solid 22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10PF 04217903 is a MET tyrosine kinase inhibitor, is also a n orally bioavailabe, small molecule tyrosine kinase inhibitor of the proto oncogene c Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. c Met inhibitor PF 04217903 selectively binds to and inhibits c Met, disrupting the c Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction